Skip to main content

Leftwich Scott's Form 4 filing

Calidi Biotherapeutics, Inc. (CLDI) · filed Aug 25, 2025

Accession no.
0001641172-25-025446
Filed
Aug 25, 2025
Trade date
Aug 21, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $250.0K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Leftwich ScottCIK 0001991668Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 21, 2025Common StockPPurchaseAcquired+125,000$2.00F2+$250,000130,650Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 21, 2025Common stockPPurchaseAcquired+125,000–F2–125,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Remarks

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated July 2, 2024.)

Read the full filing on SEC EDGAR (opens in a new tab)